Trial Profile
The effectiveness and Safety Study on Apatinib Combined With Vinorelbine Used for Driver Gene Mutation Negative Third-line and Third-line Post Progression Advanced Non-small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Vinorelbine (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 12 Feb 2020 Status changed from recruiting to completed.
- 31 May 2019 Results assessing study of apatinib combined with vinorelbine in advanced non-small cell lung cancer published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019)
- 28 Jan 2019 Phase has been changed from phase1 to phase2.